APSR2026-1011

 
Late-Breaking
Submitted
Oral Presentation
AO34-006
 
 
https://storage.unitedwebnetwork.com/files/1285/1245002-46903-Chunwa Wu AO34-006 Oral Template_433467.pptx
Format: PPTX Only
 
Format: PDF Only
08. Lung Cancer
3

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Chunwa Wu * Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Diansheng Zhong - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Linlin Zhang - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Chunwa
Wu
wawasino@163.com
 
41-50
China
Original Research
TAM-derived IL-6 induces glycolytic reprogramming to promote angiogenesis via STAT3/HIF-1α axis in non-small cell lung cancer
Maximum 25 words
Abstract Content
Tumor-associated macrophages (TAMs) and endothelial glycolytic reprogramming contribute to pathological angiogenesis and therapeutic resistance in lung cancer, but the role of TAM-derived IL-6 in regulating endothelial metabolism remains unclear. This study investigated whether TAM-secreted IL-6 promotes angiogenesis in non-small cell lung cancer (NSCLC) through the STAT3/HIF-1α-mediated glycolytic pathway.
TCGA and GEO analyses were performed to assess associations among TAM infiltration, IL-6 expression, glycolysis, and angiogenesis. M2-like TAMs, NSCLC cells, and HUVECs were used to establish co-culture and conditioned-medium models. IL-6 secretion, STAT3/HIF-1α activation, glycolysis-related proteins, glycolytic flux, endothelial migration, and tube formation were examined by ELISA, Western blot, Seahorse analysis, wound-healing assay, and Matrigel tube formation assay. A nude mouse xenograft model was used to evaluate the effects of IL-6 blockade and glycolysis inhibition in vivo.
High IL-6 expression was associated with M2-TAM infiltration and enrichment of glycolysis and angiogenesis pathways. NSCLC cell–TAM interaction markedly increased IL-6 secretion, mainly from TAMs. TAM-conditioned medium or recombinant IL-6 activated STAT3/HIF-1α signaling, upregulated GLUT1, HK2, PFKFB3, and LDHA, and enhanced endothelial glycolysis. STAT3 inhibition reversed IL-6-induced HIF-1α activation and glycolytic reprogramming, whereas HIF-1α overexpression partially rescued glycolysis. IL-6 promoted endothelial migration and tube formation, which were attenuated by STAT3 blockade or glycolysis inhibition. In vivo, IL-6 neutralization combined with glycolysis inhibition suppressed tumor growth and microvessel density.
TAM-derived IL-6 promotes NSCLC angiogenesis by inducing endothelial glycolytic reprogramming through the STAT3/HIF-1α axis, suggesting a potential therapeutic strategy for overcoming anti-angiogenic resistance.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
non-small cell lung cancer, tumor-associated macrophages, glycolytic reprogramming
maximum 3 keywords and no abbreviations, separated by commas
 
243